Clinical Trial Update: Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed State [Phase 1]

View source ↗

Summary

Phase 1 bioavailability study of PF-00868554 administered as 3x250 mg tablets (wet granulate), 3x250 mg tablets (dry granulate), and a 750 mg solution under fed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PF-00868554

Snippet

Sponsor: Pfizer | Conditions: Hepatitis C Virus | Phase 1 | Status: COMPLETED